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ABSTRACT 
 
Erythromycin has antibacterial activity and especially useful in the treatment of superficial infections 
involving conjunctivitis and/or cornea caused by organisms. Sustained drug therapies have more 
advantages than conventional. In the present study, an attempt was made to formulate sustained drug 
delivery system for Erythromycin in matrix type the formulations for Erythromycin containing 10%, 12%, 
and 14% w/v of Gelatin & Hydroxy propyl methylcellulose, and 14% , 16%, and 18% w/v for Ethyl cellulose 
were prepared by solvent casting method and evaluated for their average weight variation, thickness, drug 
content, in-vitro drug release and stability studies. An increase in average weight and thickness is due to 
increase in polymer concentration. IR spectrum revealed that there is no incompatibility and no drug-
polymer interactions. Gelatin F09, HPMC F15 and EC F21 exhibited maximum average weight 16.66 ± 0.02, 
10.81 ± 0.01 & 21.40 ± 0.01 mg respectively and thickness of 0.29 ± 0.01, 0.33± 0.06 and 0.43± 0.02mm 
respectively. The drug content was found to be 94.48, 92.87 & 90.26% respectively. Formulations containing 
16 % and 18% w/v of EC showed sustained and almost complete drug release and dissolved 86.99% and 
85.00 % over 14hours period was selected as an ideal formulation. The dissolution data of above 
formulation were subjected to first order, Higuchi’s and peppa’s equations. Stability studies conducted for 
F20 formulation. The formulation showed satisfactory physical stability at 250 C and 400C at 60% and 75% 
RH respectively. The physical appearance had not changed considerably.  
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INTRODUCTION 
Ophthalmic drug delivery is one of the most 
interesting and challenging endeavors facing the 
pharmaceutical scientists. The anatomy-physiology 
and biochemistry of the eye render this organ 
exquisitely impervious to foreign substances. The 
challenge to the formulator is to circumvent the 
protective barriers of the eye without causing 
permanent tissue damage. The development of 
newer, more sensitive diagnostic techniques and 
therapeutic agents renders urgency to the 
development of maximum successful and advanced 
ocular drug delivery systems. [1,2,3] The goal of 
pharmacotherapeutics is the attainment of an 
effective drug concentration at the intended site of 
action for a desired period of time. Eye, as a portal for 
drug delivery is generally used for the local therapy 
as against systemic therapy in order to avoid the risk 
of eye damage from high blood concentrations of 
drug which are not intended for eye.[4,5] 
Erythromycin has antibacterial activity and is used in 
treatment of superficial infections involving 
conjunctivitis and/or cornea caused by organisms 
susceptible to Erythromycin. Treatment with 
conventional drops usually associated extensive drug 
loss and systemic absorption. This result in poor 
ocular drug availability and systemic adverse effects, 
topical administration is preferred over the systemic 
mode of treating the ocular diseases conditions. [6] 
Various drug delivery approaches have been made 
reported to overcome these limitations of eye drop, 
in which ocular films are reported to exhibit sustain 
drug release and improve the corneal residence. In 
the present study an attempt was made to formulate 
ocular films of Erythromycin and evaluates their 
physical properties and in- vitro release profile. 
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MATERIALS AND METHODS 
Erythromycin was obtained as gift sample from FDC 
Pharmaceuticals Pvt. Ltd., Mumbai. Hydroxy propyl 
Methyl Cellulose K4M, Gelatin, Ethyl cellulose, 
Glycerin, Diethyl phthalate, Benzalkonium chloride, 
Alcohol, Calcium chloride, Potassium dihydrogen 
phosphate, Sodium Hydroxide were purchased from 
SD Fine Chemicals, Mumbai. 
Preparation of calibration curve for 
erythromycin 
100 mg of Erythromycin was accurately weighed and 
transferred into a 100ml volumetric flask and 
dissolved in simulated tear fluid (Sodium Chloride, 
Sodium Bi-carbonate, Calcium chloride) and made up 
to volume to 100ml using simulated tear fluid. From 
the standard stock solution, concentrations of 3, 6, 9, 
12 and 15 µg/ml, solutions were prepared. The 
absorbance of the diluted solutions was measured at 
285 nm against simulated tear fluid as blank. 
Drug Excipient Interaction Studies 
There is always possibility of drug-Excipient 
interaction in any formulation due to their intimate 
contact. The technique employed in this study 
contact. The technique employed this study was IR 
spectroscopy. 
Preparation of ocular insert 
Ocular insert of Erythromycin were prepared by 
using following polymers Gelatin, Hydroxy propyl 
methyl cellulose, Ethyl cellulose. 
Method for preparation of Gelatin films [7] 
The required quantity of gelatin and glycerin were 
weighed and dissolved in water and the mixture was 
heated at 600C on a water bath until the entire gelatin 
was dissolved. The weighed amount of Erythromycin 
(passed through sieve #400) was added and stirred 
for 6 hours at 400C on magnetic stirrer to get uniform 
dispersion. After complete mixing the casting 
solution (15ml) was poured in clean petri dish. The 
petri dish was cooled at 100C by placing on ice until 
the films were gelled. The gelled films were taken out 
from ice and allowed to dry at room temperature for 
24 hours. The dried films thus obtained were cut into 
required size (8mm diameter) by cork borer and 
stored till used.  
Method for preparation of HPMC films [8] 
The required quantity of HPMC were weighed and 
dissolved in distilled water by gentle stirring on 
Magnetic stirrer. The required amount of Glycerin 
was added as plasticizer to above solution under 
stirring condition. Weighed amount of Erythromycin, 
previously passed through sieve #400, was added 
and stirred for 6hrs to get clear solution. After 
complete mixing, the casting solution15 ml was 
poured in clean anumbra Petri dish of area 
63.64sq.cm. Then the Petri dish was dried at room 
temperature for 24hrs. The dried films thus obtained 
were cut into size of mm diameter by cork borer, 
wrapped in aluminum file and stored till used.  
Method for preparation of ethyl cellulose films [9] 
Preparation of ethyl cellulose films: Accurately 
weighed quantity of polymer was dissolved in alcohol 
containing diethylphalate as plasticizer 40 w/w% of 
polymer. Weigh and transfer required quantity of 
Ethyl cellulose to this solution and stir for about 2 
hours. Allow to stand overnight and then placed 
under vacuum to remove air bubbles. The polymeric 
drug solution 15 ml was then poured into 
relubricated glass mould and allows to get dried at 
50˚C for 6 hours in hot air oven. After drying, the films 
were removed and cut into circular disc of 8 mm 
diameter.  
Evaluation of the prepared formulations [10, 11, 12] 
Uniformity of thickness: Five films were taken from 
each batch and their individual thickness was 
measured using micrometer screw gauge. 
Uniformity of weight: Five films were taken from 
each batch and their individual weights were 
determined by using electronic balance. 
Uniformity of drug content: Three films were taken 
from each batch and individually dissolved or 
crushed in 5 ml of simulated tear fluid in a beaker and 
filter it into the beaker.0.5 ml of the filtered solution 
was taken in 20 ml beaker and diluted to 15 ml with 
simulated tear fluid. Three reading were taken using 
Shimadzu-160A UV spectrophotometer at 233 nm. 
Swelling index: Three films were weighed and 
placed separately in beakers containing 4ml of 
distilled water. After a period of 5 minutes, the films 
were removed and the excess water on their surface 
was removed using a filter paper and then again 
weighed till there was no increase in the weight. The 
swelling index was then calculated by dividing the 
increase in weight by the original weight and was 
expressed as percentage. 
In-vitro dissolution studies of formulations using 
the vial method [13] 
The in-vitro dissolution of drug from the different 
ocular inserts was studied using the vial method. 
Each insert was placed in 10 ml capacity vials 
containing 5 ml of simulated tear fluid that was 
previously warmed at 37±1˚C. These vials were 
placed over hot plate (maintained at room 
temperature 37±1˚C) that was positioned on a sieve 
shaker. Shaker was kept at minimum shaking speed 
to simulated the blinking of eye. Aliquots of 5ml 
samples at specific interval of time were withdrawn 
carefully using pipette and equivalent amount of 
fresh dissolution fluid was replaced. The aliquots 
withdrawn were suitably diluted with simulated tear 
fluid and was analyzed at 285 nm using Shimadzu- 
160A UV Spectrophotometer against blank. 
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Table 1: Formulation table 
Ingredients 
F1 F2 F3 F4 F5 F6 F7 F8 F9 F10 F11 F12 F13 F14 F15 F16 F17 F18 F19 F20 F21 
10% w/v 12% w/v 14% w/v 10% w/v 10% w/v 12% w/v 14% w/v 16% w/v 18% w/v 
Drug (mg) 25 25 25 25 25 25 25 25 25 25 25 25 25 25 25 25 25 25 25 25 25 
Gelatin (gm) 1.5 1.5 1.5 1.8 1.8 1.8 2.1 2.1 2.1 - - - - - - - - - - - - 
HPMC(gm) - - - - - - - - - 1.5 1.5 1.8 1.8 2.1 2.1 - - - - - - 
EC (gm) - - - - - - - - - - - - - - - 2.1 2.1 2.4 2.4 2.7 2.7 
Glycerin (ml)  
(40% w/w of polymer) 
0.47 - - 0.57 - - 0.67 - - 0.47 - 0.57 - 0.67 - - - - - - - 
Glycerin (ml) 
(50% w/w of polymer) 
- 0.59 - - 7.1 - - 0.83 - - 0.59 - 0.7 - 0.83 - - - - - - 
Glycerin (ml)  
(60% w/w of polymer) 
- - 0.7 - - 0.85 - - 1.0 - - - -   - - - - - - 
DEP (ml) 
(40% w/w of polymer) 
- - - - - - - - - - - - - - - 0.75  0.86 - 0.96 - 
DEP (ml) 
(50% w/w of polymer) 
- - - - - - - - - - - - - - - - 0.93 - 1.07 - 1.20 
Water (ml) 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 - - - - - - 
Alcohol (ml) - - - - - - - - - - - - - - - 15 15 15 15 15 15 
Benzyl Alkonium Choloride 
(ml) 
0.0012 0.0012 0.0012 0.0012 0.0012 0.0012 0.0012 0.0012 0.0012 0.0012 0.0012 0.0012 0.0012 0.0012 0.0012 0.0012 0.0012 0.0012 0.0012 0.0012 0.0012 
 
 
Figure 1: Ocular Inserts of Erythromycin using Gelatin as 
polymer 
 
Figure 2: Ocular Inserts of Erythromycin using HPMC as poly-
mer 
 
Figure 3: Ocular Inserts of Erythromycin using Ethyl cellu-
lose as polymer 
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Table 2: Physico-chemical Evaluation of Ocular Inserts 
Formulations Weight in (mg) + SD Thickness in (m) + SD Swelling Index (%) % Drug content 
F1 11.1 ± 0.0101 0.19±0.01 1.30 ± 0.0220 98.68 ± 0.03 
F2 17.4 ± 0.0121 0.26±0.01 1.85 ± 0.0103 95.33 ± 0.07 
F3 12.8 ± 0.0113 0.22 ± 0.07 1.98 ± 0.0111 99.00 ± 0.05 
F4 13.2 ± 0.0134 0.27 ± 0.05 2.14 ± 0.0114 98.30 ± 0.05 
F5 14.76 ± 0.0212 0.28±0.05 2.18 ± 0.0124 99.41 ± 0.02 
F6 18.33 ± 0.0100 0.30 ± 0.03 2.29 ± 0.0231 97.74 ± 0.04 
F7 20.66 ± 0.0242 0.31 ± 0.03 2.40 ± 0.0241 93.49 ± 0.05 
F8 16.73 ± 0.0112 0.28 ± 0.02 2.83 ± 0.0101 98.55 ± 0.03 
F9 16.66 ± 0.0212 0.29 ± 0.01 2.86 ± 0.0114 94.48 ± 0.02 
F10 10.8 ± 0.0210 0.25 ± 0.07 1.35 ± 0.0112 99.38 ± 0.21 
F11 11.37± 0.0211 0.30 ± 0.04 1.42 ± 0.0224 93.40 ± 0.09 
F12 18.53 ± 0.0118 0.29 ±0.02 1.96 ± 0.0218 91.76 ± 0.01 
F13 14.59 ± 0.0134 0.31 ± 0.04 2.28 ± 0.0113 93.66 ± 0.02 
F14 12.21± 0.0123 0.34 ±0.05 2.32 ± 0.0213 99.79 ±0.01 
F15 10.81± 0.0121 0.33 ± 0.06 2.36 ± 0.0311 92.87 ± 0.09 
F16 16.52± 0.0102 0.30 ± 0.02 1.37 ± 1.0101 98 ± 0.02 
F17 19.31 ± 0.0211 0.38 ± 0.04 1.29 ± 1.0112 98.18 ± 0.01 
F18 22.66 ± 0.0211 0.44 ± 0.02 1.22 ± 0.0215 91.32 ± 0.03 
F19 20.76 ± 0.0202 0.39 ± 0.01 1.19 ± 0.0312 94.84 ± 0.07 
F20 22.66 ± 0.0021 0.43 ± 0.04 1.16 ± 0.0101 96.60 ± 0.07 
F21 18.4 ± 0.0031 0.43± 0.02 1.06 ± 0.0108 90.26 ± 0.03 
Table 3: In vitro drug release for F1- F9 formulations in Simulated tear fluid 
Time (min) Formulations 
F1 F02 F03 F04 F05 F06 F07 F08 F09 
30 61.353 64.397 68.193 56.919 59.855 64.799 56.465 58.301 63.242 
60 69.409 70.902 77.260 66.599 70.825 76.189 64.890 69.186 73.332 
120 96.163 97.127 98.984 95.188 96.259 97.734 91.778 94.009 96.172 
180 - - - - - - - 97.796 99.232 




F10 F11 F12 F13 F14 F15 F16 F17 F18 F19 F20 F21 
30 54.279 56.111 54.177 55.695 52.111 55.053 24.427 23.720 22.263 21.893 21.958 20.365 
60 64.334 68.584 63.279 67.308 63.030 65.725 31.780 28.905 31.807 31.425 29.343 28.901 
120 77.902 86.279 69.841 77.167 69.334 76.420 36.122 34.824 35.957 33.137 34.653 33.115 
180 91.001 96.129 88.102 90.007 86.875 88.113 37.413 34.976 36.309 34.098 35.402 34.895 
240 - - 96.068 98.325 95.45 97.874 38.950 38.137 39.947 38.354 38.086 37.552 
300 - - - - - - 41.687 41.016 39.982 38.837 37.926 37.536 
360 - - - - - - 44.079 43.216 43.783 41.056 42.357 40.662 
420 - - - - - - 52.113 49.037 51.092 49.235 50.137 49.342 
480 - - - - - - 61.252 58.124 59.146 59.002 58.053 57.900 
540 - - - - - - 68.324 63.891 64.024 62.986 62.837 59.496 
600 - - - - - - 74.903 71.012 73.896 69.670 71.198 67.794 
660 - - - - - - 81.106 78.982 78.001 76.159 76.854 75.164 
720 - - - - - - 86.996 83.581 85.785 82.026 84.920 82.111 
780 - - - - - - - - 86.142 85.881 85.721 84.341 
840 - - -- - - - - - 88.969 86.432 86.005 85.002 
Table 5: Stability studies For F18  
Stored at 25 0C/ 60 % RH Stored 400 C / 75 % RH 
Time in weeks Physical appearance % Drug content Physical appearance % Drug content 
0 +++ 95.14 +++ 97.12 
2 +++ 96.54 +++ 94.26 
4 +++ 99.78 +++ 96.48 
6 +++ 98.20 ++ 95.28 
8 ++ 96.47 ++ 94.91 
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Stability Studies: As per ICH guidelines the selected 
formulations were stored at 250C/60%RH and 
400C/75/RH for 2 months and evaluated for their 
physical appearance and drug content at specific 
period. 
Table 6: Calibration Curve Data of Erythromycin in 
Simulated tear fluid 
S.No Conc.(g/l) Absorbance 
1 0 0 
2 3 0.023 
3 6 0.045 
4 9 0.065 
5 12 0.085 
6 15 0.103 
 
Figure 4: Calibration Curve of Erythromycin in Simu-
lated tear fluid 
 
Figure 5: FT-IR of Erythromycin pure drug 
 
Figure 6: FT-IR Study for Erythromycin+ EC 
 
Figure 7: FT-IR Study for Erythromycin+ Gelatin 
 
Figure 8: FT-IR Study for Erythromycin+ HPMCK4M 
RESULTS AND DISCUSSION 
Characteristic absorption bands of Erythromycin 
seen in the IR spectra of pure drug were also seen in 
the IR spectra of prepared formulations, indicating 
that there was no interaction between drug and 
formulation components. The thickness of the 
formulations determined by micrometer screw gauge 
varied between 0.19±0.01 to 0.440±0.02 mm showed 
that the thickness was uniform and the formulation 
did not produce any irritation when placed in the cul 
de sac since they were not thick enough to produce 
irritation. Uniformity of weight determined by 
electronic balance results showed that the weights of 
formulation were between 11.10±0.01 to 22.66± 
0.02mg.  
The drug content of the formulations was determined 
and results showed that the drug content in all 
formulation was found to contain 90.26±0.03 % to 
99.79±0.01 % of Erythromycin. The swelling index of 
formulations was between 1.30±0.02 to 2.86±0.01 
and showed that there was no much variation in the 
water absorption properties of formulation. In vitro 
dissolution studies were carried out using procedure 
as mentioned in section IV methods, the release 
profile of the formulation is shown in the table 3 & 4.  
The release of the drug from formulations F1, F2, F3 
containing 10% Gelatin was found to be 96.16%, 
97.12% & 98.98% at the end of 2nd hr respectively, 
the release of the drug from formulation F4, F5 & F6 
containing 12% Gelatin was found to be 95.18%, 
96.25% & 97.73% at the end of 2nd hr respectively. 
The release of the drug from the formulations F7, F8, 
F9 containing 14% Gelatin was found to be 91.77%, 
97.79% & 99.23 % at the end of 3rd hr respectively. 
The release of the drug from the formulations F10 & 
F11containing 10% of HPMC K4M was found to be 
91.00% & 96.12% at the end of 3rd hr respectively. 
The release of the drug from the formulations F12 & 
F13containing 12% HPMC K4M was found to be 
96.06% & 98.32% at the end of 4th hr respectively. 
The release of the drug from the formulations F14 & 
F15 containing 14 % HPMC K4M was found to be 
95.45% & 97.87% at the end of 4th hr respectively.  
Similarly, The release of the drug from the 
formulations F16 & F17 containing 14% EC was 
found to be 86.99% & 83.58% at the end of 12th hr 
respectively. The release of the drug from the 
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formulations F18 & F19 containing 16 % EC was 
found to be 85.78% & 82.02% at the end of 12th hr 
respectively. The release of the drug from the 
formulations F20 & F21 containing 18% EC was 
found to be 84.92% & 82.11 at the end of 12th hr 
respectively. 
From the dissolution studies it is concluded that as 
the concentration of gelatin increases, drug release 
from the formulation decreases. The formulation 
with gelatin as polymer showed complete release of 
drug in 2 to 3hrs. As the concentration of glycerin in 
formulation is increased drug release was increased, 
which could be attributed to its high rate and extent 
of swelling. This finding was also supported by 
results of swelling studies where the highest swelling 
index was exhibited by the formulation containing 
highest concentration of glycerin, indicating that 
increase in water soluble plasticizer (glycerin) 
content results in faster swelling and release from 
ocular inserts. 
As the concentration of HPMC increases, drug release 
from the formulation decreases. The formulation 
with HPMC as polymer showed complete release of 
drug in 3 to 4hrs. As the concentration of glycerin in 
formulation is increased drug release was increased, 
which could be attributed to its high rate and extent 
of swelling. This finding was also supported by 
results of swelling studies where the highest swelling 
index was exhibited by the formulation containing 
highest concentration of glycerin, indicating that 
increase in water soluble plasticizer (glycerin) 
content results in faster swelling and release from 
ocuserts. 
As the concentration of EC increases, drug release 
from the formulation decreases. The finding was also 
supported by the result of swelling studies where the 
lowest swelling index was exhibited by the 
formulation containing highest concentration of ethyl 
cellulose; this is due to the hydrophobic nature of 
ethyl cellulose. 
The release data were also subjected to model fitting 
analysis to know the mechanism of drug release from 
the formulation by treating the data according to 
zero, first order, Higuchi’s and peppa’s equation. The 
results are shown in the table.24 & 25. The linearity 
and slope indicate that the release of drug from the 
films have followed First order model and non fickian 
nature. The Higuchi plots reveled that the release of 
drug to be by diffusion controlled mechanism. 
From the above discussions it can be concluded that 
formulation containing EC 14, 16 and 18 % w/v i.e, 
F16, F18 and F20 has achieved the objectives of 
increased contact time, prolonged release, and 
decreased frequency of administration and thus may 
improve the patient compliance.  
CONCLUSION 
In the Present research work Erythromycin ocular 
inserts were prepared using Gelatin, HPMC & EC as 
base polymer by solvent casting technique. FT-IR 
spectral analysis showed that characteristic peak of 
Erythromycin pure drug was retained in the spectra 
of all the formulations, indicating the intactness of the 
drug in all the formulations. The prepared ocular 
insert were evaluated for number of parameters like 
physical appearance, surface texture, weight 
uniformity, thickness of ocular insert, swelling index, 
drug excipient interaction studies, drug uniformity 
and in vitro drug release. All the prepared ocular 
insert were of smooth surface and elegant texture. All 
the prepared ocular insert of Gelatin, HPMC & EC in 
different concentrations (10, 12, 14, 16 and 
18%w/v). The prepared ocular insert were checked 
visually for its appearance & surface texture. All the 
prepared patches were of smooth surface & elegant 
texture. The weights of the ocular insert were in the 
range of 11.10 ± 0.0101 and 22.60 ±0.0242mg. The 
thickness of the ocular insert was in the range of 
0.19±0.01to 0.44 ± 0.02 mm. Drug content uniformity 
study showed uniform dispersion of the drug 
throughout the formulation in the range of 91.32 ± 
0.03 to 99.79 ± 0.01%. In vitro drug release studies 
showed that more than 86% of the drug was released 
at the end of 12th hrs from EC formulations. The 
formulations were also subjected to model fitting 
analysis to know the mechanism of drug release from 
the formulations by treating the data according to 
zero, first – order, Higuchi and peppa’s equations. The 
data clearly shows that, all the formulations followed 
first order and the mechanism of drug release from 
all batches followed non-fickian diffusion Based on 
results obtained the formulation F18 has shown the 
best drug release was tested for stability studies 8 
weeks at storage condition of 250 C and 400C at 60% 
and 75% RH and results reveal that the physical 
appearance had not changed considerably.  
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